Amgen Financial Ratios

Amgen Inc -- USA Stock  

USD 170.12  0.16  0.0941%

We suggest you to use Amgen Inc fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Amgen Inc is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-eight available fundamental indicators for Amgen Inc which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Amgen Inc fundamentals including its EBITDA, Cash Flow from Operations and the relationship between Price to Book and Total Debt . Given that Amgen Inc has Price to Earning of 15.47 times, we suggest you validate Amgen Inc prevailing market performance to make sure the company can sustain itself down the road.Use Amgen to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of Amgen to be traded at $178.63 in 30 days

Amgen Inc Valuation Over Time

Enterprise Value

Amgen Company Summary

Amgen competes with Vertex Pharmaceuticals, Endo International, Abbott Laboratories, Allergan plc, and BIO RAD. It offers solutions for the treatment of illness in the areas of oncologyhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen Incs solutions include Neulasta, a pegylated protein for the treatment of cancer patients NEUPOGEN, a recombinantmethionyl human granulocyte colonystimulating factor for reducing the incidence of infection for patients with nonmyeloid malignancies and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its solutions also comprise EPOGEN to treat a lowerthannormal number of red blood cells caused by chronic kidney disease in patients on dialysis Aranesp for treating anemia XGEVA for the prevention of skeletalrelated events Prolia to treat postmenopausal women with osteoporosis Repatha for the treatment of cholesterol and SensiparMimpara solutions for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Amgen Incs other marketed solutions include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and smallcell lung cancer Nplate, a thrombopoietic compound Vectibix, a human monoclonal antibody and BLINCYTO for the treatment of patients with Philadelphia chromosomenegative relapsed or refractory Bcell precursor acute lymphoblastic leukemia. It also develops various solutions that are in various clinical trials. Amgen Inc serves pharmaceutical wholesale distributors and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc UCB Novartis AG Bayer HealthCare Pharmaceuticals Inc Advaxis, Inc. Dr. Reddys Laboratories Ltd. Biocartis Group NV and Nuevolution AB. Amgen Inc also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Amgen Book Value Per Share vs Current Asset

Amgen Inc is rated third in book value per share category among related companies. It is number one stock in current asset category among related companies fabricating about  887,307,072  of Current Asset per Book Value Per Share.

Amgen Inc Systematic Risk

The output start index for this execution was fourteen with a total number of output elements of three. The Beta measures systematic risk based on how returns on Amgen Inc correlated with the market. If Beta is less then 0 Amgen generally moves in the opposite direction as compared to the market. If Amgen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amgen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amgen is generally in the same direction as the market. If Beta > 1 Amgen moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 39% 

Chance of Financial Distress

Amgen Inc has less than 39 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Amgen Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Amgen To Peers
Robert Bradway Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Brian McNamee Executive Vice President - Full Potential Initiatives
More Executives

Opportunity Range

November 24, 2017 Opportunity Range